BridgeBio Oncology Therapeutics (BBOT) is a newly spun-out company from BridgeBio dedicated to creating a pipeline of oral small-molecule drugs for RAS- and PI3K-mutant malignancies. The company’s lead asset, BBO-8520, is a direct KRAS inhibitor that binds both the active and inactive conformations of the protein and is already enrolling mutant non-small cell lung cancer patients in a Phase Ia/Ib study. Its second program, BBO-10203, is a PI3Kα:RAS breaker that disrupts the RAS–PI3Kα interaction; BBOT plans to file an IND in Q2 2024 and begin patient enrollment later this year. A third candidate, BBO-11818, is a pan-KRASG12X inhibitor with an IND submission targeted for early 2025. Beyond these three clinical and near-clinical programs, BBOT is running discovery-stage research to address additional oncogenic drivers within the RAS and PI3K signaling axes. Originally incorporated as TheRas in 2016, the unit operated under a 2017 R&D agreement with Leidos Biomedical Research before its formal spinout. BBOT is led by Eli Wallace (CEO, Oncology R&D) with BridgeBio CEO Neil Kumar serving as a director, and it is currently financed by a recently closed $200 million round that will fund progression of all three pipeline assets into the clinic over the next 12 months.

Total raised

$200M

Funding rounds

1

Latest round

Equity

Latest activity

May 2024